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Abstract
Soybean DAS-68416-4 was developed by Agrobacterium tumefaciens-mediated transformation to
express the aryloxyalkanoate dioxygenase-12 (AAD-12) protein, conferring tolerance to 2,4-
dichlorophenoxyacetic acid (2,4-D) and other related phenoxy herbicides, and the phosphinothricin
acetyltransferase (PAT) protein, conferring tolerance to glufosinate ammonium-based herbicides. The
molecular characterisation data and bioinformatics analyses did not identify issues requiring further
assessment for food/feed safety. The agronomic and phenotypic characteristics tested revealed no
relevant differences between soybean DAS-68416-4 and its conventional counterpart, except for ‘days to
50% ﬂowering’. The compositional analysis identiﬁed no differences requiring further assessment,
except for an increase (up to 36%) in lectin activity in soybean DAS-68416-4. Such increase is unlikely to
raise additional concerns for food/feed safety and nutrition for soybean DAS-68416-4 as compared to its
conventional counterpart and the non-GM reference varieties. There were no concerns regarding the
potential toxicity and allergenicity of the two newly expressed proteins, and no evidence that the genetic
modiﬁcation might signiﬁcantly change the overall allergenicity of soybean DAS-68416-4. Soybean DAS-
68416-4 is as nutritious as its conventional counterpart and the non-GM reference varieties. There are
no indications of an increased likelihood of establishment and spread of occasional feral soybean DAS-
68416-4 plants, unless these are exposed to the intended herbicides. The likelihood of environmental
effects resulting from the accidental release of viable seeds from soybean DAS-68416-4 into the
environment is therefore very low. The post-market environmental monitoring plan and reporting
intervals are in line with the intended uses of soybean DAS-68416-4. The GMO Panel concludes that the
information available addresses the scientiﬁc comments of the Member States and that soybean DAS-
68416-4, as described in this application, is as safe as its conventional counterpart and the tested non-
GM reference varieties with respect to potential effects on human and animal health and the
environment in the context of the scope of this application.
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Summary
Following the submission of an application (EFSA-GMO-NL-2011-91) under Regulation (EC)
No 1829/2003 from Dow AgroSciences LLC, the Panel on Genetically Modiﬁed Organisms of the
European Food Safety Authority (GMO Panel) was asked to deliver a scientiﬁc opinion on the safety of
the genetically modiﬁed (GM) herbicide-tolerant soybean (Glycine max L.) DAS-68416-4 (Unique
Identiﬁer DAS-68416-4). The scope of application EFSA-GMO-NL-2011-91 is for import, processing, and
food and feed uses of soybean DAS-68416-4 within the European Union (EU), but excludes cultivation
in the EU.
The GMO Panel evaluated soybean DAS-68416-4 with reference to the scope and appropriate
principles described in its guidelines for the risk assessment of GM plants. The evaluation addressed
the following components of the risk assessment: the molecular characterisation of the inserted DNA
and analysis of the expression of the corresponding proteins; the comparative analyses of
compositional, agronomic and phenotypic characteristics; the safety of the newly expressed proteins
and the whole food/feed with respect to potential toxicity, allergenicity and nutritional characteristics;
the environmental risk assessment; and the post-market environmental monitoring plan.
Soybean DAS-68416-4 was developed by Agrobacterium tumefaciens-mediated transformation. It
expresses the aryloxyalkanoate dioxygenase-12 (AAD-12) protein, conferring tolerance to 2,4-
dichlorophenoxyacetic acid (2,4-D) and other related phenoxy herbicides, and the phosphinothricin
acetyltransferase (PAT) protein, conferring tolerance to glufosinate ammonium-based herbicides. The
molecular characterisation data established that soybean DAS-68416-4 contains one insert consisting
of two expression cassettes, aad-12 and pat. No other parts of the plasmid used for transformation
were detected in soybean DAS-68416-4. Bioinformatic analyses and genetic stability studies were
performed and the results did not identify issues requiring further assessment for food/feed safety. The
levels of the newly expressed proteins present in soybean DAS-68416-4 were obtained and reported
adequately.
The agronomic and phenotypic characteristics of soybean DAS-68416-4 tested revealed no relevant
differences between soybean DAS-68416-4 and its conventional counterpart, except for ‘days to 50%
ﬂowering’ for the GM soybean not treated with the intended herbicides. The difference observed in
‘days to 50% ﬂowering’ was further assessed for its potential environmental impact. No differences in
composition requiring further assessment for food/feed safety were found between soybean DAS-
68416-4 and its conventional counterpart, except for a higher lectin activity (up to 36%) in two of the
four treatments of soybean DAS-68416-4.
The increase in lectin activity is unlikely to raise additional concerns for food/feed safety and
nutrition for soybean DAS-68416-4 as compared to its conventional counterpart and the non-GM
commercial varieties. The safety assessment identiﬁed no concerns regarding the potential toxicity and
allergenicity of the newly expressed PAT and AAD-12 proteins in soybean DAS-68416-4, and found no
evidence that the genetic modiﬁcation might signiﬁcantly change the overall allergenicity of soybean
DAS-68416-4. The GMO Panel concludes that soybean DAS-68416-4 is as safe and as nutritious as its
conventional counterpart and the non-GM soybean reference varieties. The GMO Panel considers that
post-market monitoring of food/feed derived from soybean DAS-68416-4 is not necessary, given the
absence of safety concerns identiﬁed.
Considering the scope of this application, the environmental risk assessment is concerned with the
accidental release into the environment of viable soybean DAS-68416-4 seeds (i.e. during transport
and/or processing), and with the exposure of bacteria to recombinant DNA in the gastrointestinal tract
of animals fed GM material and those present in environments exposed to their faecal material
(manure and faeces).
In the case of accidental release into the environment of viable seeds of soybean DAS-68416-4,
there are no indications of an increased likelihood of establishment and spread of occasional feral
soybean DAS-68416-4 plants, unless these plants are exposed to the intended herbicides. This will not
result in different environmental impacts compared to conventional soybean. Considering the scope of
the application EFSA-GMO-NL-2011-91, interactions with the biotic and abiotic environment are not
considered to be relevant issues. Bioinformatic analyses of the inserted DNA identiﬁed sufﬁcient
sequence identity with bacterial DNA which could theoretically facilitate the transfer of a plant codon-
optimised pat gene onto a plasmid of a soil bacterium. Illegitimate transfer of a plant-optimised aad-12
gene was also considered. Based on the functional proteins encoded by these genes and their
expected prevalence in environmental bacteria, the GMO Panel did not identify a concern in relation to
horizontal gene transfer to bacteria. Therefore, considering the introduced traits, the outcome of the
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comparative analysis, the routes of exposure and the limited exposure levels, the GMO Panel concludes
that soybean DAS-68416-4 would not raise safety concerns in the event of accidental release of viable
GM soybean seeds into the environment. The scope of the post-market environmental monitoring plan
provided by the applicant and the reporting intervals are in line with the intended uses of soybean
DAS-68416-4 and the GMO Panel guidelines on the post-market environmental monitoring of GM
plants.
In delivering its scientiﬁc opinion, the GMO Panel took into account application EFSA-GMO-NL-2011-91,
additional information provided by the applicant, scientiﬁc comments submitted by the Member States
and relevant scientiﬁc publications. In conclusion, the GMO Panel considers that the information available
for soybean DAS-68416-4 addresses the scientiﬁc comments raised by the Member States and that
soybean DAS-68416-4, as described in this application, is as safe as its conventional counterpart and the
tested non-GM soybean reference varieties with respect to potential effects on human and animal health
and the environment in the context of the scope of this application.
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1. Introduction
Soybean DAS-68416-4 was developed to confer tolerance to 2,4-dichlorophenoxyacetic acid (2,4-D)
and glufosinate ammonium-based herbicides. Tolerance to 2,4-D and other related phenoxy herbicides is
provided by the expression of the aryloxyalkanoate dioxygenase-12 (AAD-12) protein from
Delftia acidovorans. Tolerance to glufosinate ammonium-based herbicides is provided by the expression
of the phosphinothricin acetyltransferase (PAT) protein from Streptomyces viridochromogenes.1
The assessment of potential consumer health risks resulting from 2,4-D residues and its metabolites
in soybean DAS-68416-4 is outside the remit of the GMO Panel and needs to be performed upon
request of an applicant in the framework of Regulation (EC) No 396/2005.
1.1. Background
On 25 January 2011, the European Food Safety Authority (EFSA) received from the Competent
Authority of the Netherlands an application (Reference EFSA-GMO-NL-2011-91) for authorisation of
genetically modiﬁed (GM) soybean DAS-68416-4 (Unique Identiﬁer DAS-68416-4), submitted by Dow
AgroSciences LLC within the framework of Regulation (EC) No 1829/2003 on GM food and feed.2
After receiving the application EFSA-GMO-NL-2011-91, and in accordance with Articles 5(2)(b)
and 17(2)(b) of the Regulation (EC) No 1829/2003, EFSA informed the Member States and the
European Commission, and made the summary of the application publicly available on the EFSA
website.3 EFSA initiated a formal review of the application to check compliance with the requirements
laid down in Articles 5(3) and 17(3) of the Regulation (EC) No 1829/2003. On 23 March 2011,
5 May 2011, 27 June 2011 and 19 August 2011 EFSA received additional information requested under
completeness check (on 4 March 2011, 12 April 2011, 24 May 2011 and 20 July 2011, respectively).
On 8 September 2011, EFSA declared the application as valid in accordance with Articles 6(1) and
18(1) of Regulation (EC) No 1829/2003.
EFSA made the valid application available to the Member States and the European Commission, and
consulted nominated risk assessment bodies of Member States, including national Competent
Authorities within the meaning of Directive 2001/18/EC4 following the requirements of Articles 6(4)
and 18(4) of Regulation (EC) No 1829/2003, to request their scientiﬁc opinion. Member States had
3 months after the date of receipt of the valid application (until 8 December 2012) to make their
opinion known.
The GMO Panel requested additional information from the applicant on 5 December 2011,
30 January 2012, 20 April 2012,7 September 2012, 1 July 2014, 28 November 2014, 16 February 2015,
19 February 2015, 6 March 2015, 1 April 2015, 24 June 2015, 15 September 2015, 2 October 2015,
23 March 2016, 26 April 2016 (EURL-JRC), 26 May 2016 and 29 September 2016. The applicant provided
the requested information on 13 April 2012, 15 May 2012, 18 October 2013, 2 September 2014,
16 December 2014, 19 February 2015, 12 March 2015, 16 March 2015, 11 June 2015, 22 July 2015,
25 September 2015, 26 April 2016 (EURL-JRC), 29 April 2016, 13 May 2016, 13 June 2016 and 26
October 2016. The applicant also spontaneously provided additional information on 7 August 2012,
27 August 2012, 22 December 2015, 31 March 2016 (EURL sequence info) and 13 May 2016.
In the frame of contract OC/EFSA/UNIT/GMO/2013/01 – CT01, the contractor performed preparatory
work and delivered reports on the methods applied by the applicant in performing bioinformatic
analyses.
On 7 September 2016, the European Union Reference Laboratory (EURL-JRC) submitted to
EFSA the report on the veriﬁcation of sequencing data on event DAS-68416-4 received from the
applicant.
In giving its scientiﬁc opinion on soybean DAS-68416-4 to the European Commission, Member States
and the applicant, and in accordance with Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003,
EFSA has endeavoured to respect a time limit of 6 months from the acknowledgement of the valid
application. As additional information was requested by the GMO Panel, the time limit of 6 months was
extended accordingly, in line with Articles 6(1), 6(2), 18(1) and 18(2) of Regulation (EC) No 1829/2003.
1 Dossier: Part I – Section D1.
2 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modiﬁed
food and feed. OJ L 268, 18.10.2003, p. 1–23.
3 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2011-00052
4 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the
environment of genetically modiﬁed organisms and repealing Council Directive 90/220/EEC. OJ L 106, 12.3.2001, p. 1–38.
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According to Regulation (EC) No 1829/2003, this scientiﬁc opinion is to be seen as the report
requested under Articles 6(6) and 18(6) of that Regulation and thus will be part of the EFSA overall
opinion in accordance with Articles 6(5) and 18(5).
1.2. Terms of Reference as provided by the requestor
The GMO Panel was requested to carry out a scientiﬁc assessment of soybean DAS-68416-4 for
food and feed uses, import and processing in accordance with Articles 6(6) and 18(6) of Regulation
(EC) No 1829/2003.
Where applicable, any conditions or restrictions which should be imposed on the placing on the
market and/or speciﬁc conditions or restrictions for use and handling, including post-market monitoring
requirements based on the outcome of the risk assessment and, in the case of GMOs or food/feed
containing or consisting of GMOs, conditions for the protection of particular ecosystems/environment
and/or geographical areas should be indicated in accordance with Articles 6(5)(e) and 18(5)(e) of
Regulation (EC) No 1829/2003.
The GMO Panel was not requested to give an opinion on information required under Annex II to
the Cartagena Protocol. Furthermore, the GMO Panel did not consider proposals for labelling and
methods of detection (including sampling and the identiﬁcation of the speciﬁc transformation event in
the food/feed and/or food/feed produced from it), which are matters related to risk management.
2. Data and methodologies
2.1. Data
In delivering its scientiﬁc opinion, the GMO Panel took into account application EFSA-GMO-NL-2011-91,
additional information provided by the applicant, scientiﬁc comments submitted by the Member States
and relevant scientiﬁc publications.
2.2. Methodologies
The GMO Panel carried out a scientiﬁc risk assessment of soybean DAS-68416-4 for food and feed
uses, import and processing in accordance with Articles 6(6) and 18(6) of Regulation (EC) No 1829/
2003. The GMO Panel took into account the appropriate principles described in its guidelines for the
risk assessment of GM plants and derived food and feed (EFSA, 2006a; EFSA GMO Panel, 2011a), the
environmental risk assessment (ERA) of GM plants (EFSA GMO Panel, 2010a) and the post-market
environmental monitoring (PMEM) of GM plants (EFSA GMO Panel, 2011b).
The comments raised by Member States are addressed in Annex G of EFSA’s overall opinion3 and
were taken into consideration during the scientiﬁc risk assessment.
3. Assessment
3.1. Molecular characterisation
3.1.1. Evaluation of relevant scientiﬁc data
3.1.1.1. Transformation process and vector constructs
Soybean DAS-68416-4 was developed by Agrobacterium tumefaciens (also known as
Rhizobium radiobacter)-mediated transformation of cotyledonary nodes of soybean (Glycine max (L.)
Merr.) line Maverick with the A. tumefaciens strain EHA101 containing the binary plasmid pDAB4468.
The plasmid pDAB4468 contained two expression cassettes, aad-12 and pat, between the right and
left borders of the T-DNA.5
The aad-12 expression cassette contains the following genetic elements: the constitutive
Arabidopsis thaliana polyubiquitin UBQ10 promoter, 5’-untranslated region and intron; a codon-
optimised version of the aad-12 gene from D. acidovorans; and the 3’-untranslated region from the
open reading frame (ORF) 23 of A. tumefaciens pTi15955 (AtuORF23), which includes a transcription
terminator. The RB7-MAR matrix attachment region from Nicotiana tabacum was positioned next to
the aad-12 expression cassette to increase expression of the aad-12 gene.
5 Dossier: Part I – Sections C2 and C3.
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The pat expression cassette consisted of the following elements: the promoter and 5’-untranslated
region from the Cassava vein mosaic virus (CsVMV); a codon-optimised version of the pat gene from
the bacterium S. viridochromogenes; and the 3’-untranslated region from the ORF1 of A. tumefaciens
pTi15955 (AtuORF1), which includes a terminator and a polyadenylation site.
The vector backbone contained elements necessary for the maintenance and selection of the
plasmid in bacteria.
3.1.1.2. Transgene constructs in the GM plant6
Molecular characterisation of soybean DAS-68416-4 was performed by Southern analysis,
polymerase chain reaction (PCR) and DNA sequence analysis, in order to determine copy number, size
and organisation of the inserted sequences and to conﬁrm the absence of plasmid backbone
sequences. The approach used was acceptable both in terms of coverage and sensitivity.
Southern analysis indicated that soybean DAS-68416-4 contains a single insert, which consists of a
single copy of the T-DNA in the same conﬁguration as in the pDAB4468 vector. The insert and copy
number were conﬁrmed using multiple combinations of restriction endonucleases and 19 probes that
covered all elements of the plasmid. No elements from the vector backbone were detected.7
The nucleotide sequence of the entire insert of soybean DAS-68416-4, together with 2,730 bp of
the 5’ and 1,082 bp of 3’ ﬂanking regions, was determined. The EURL-JRC checked the compliance of
the sequencing data provided for event DAS-68416-4 with the requirements of its guidance.8 The
insert of 6,400 bp is identical to the T-DNA of pDAB4468, except for the insertion of 9 bp at the 3’ end
of the insert. A comparison of the sequences of the ﬂanking regions with that of the pre-insertion
locus indicated that 55 bp were deleted from soybean genomic DNA. No evidence was found for the
interruption of any known endogenous gene in the soybean genome.
The results of segregation (Section 3.1.1.4.) and bioinformatic analyses established that the insert
is located in the nuclear genome.9
Updated bioinformatic analyses of the amino acid sequences of the newly expressed AAD-12 and
PAT proteins revealed no signiﬁcant similarities to toxins and allergens. In addition, updated
bioinformatics analyses of the newly created ORFs present within the insert or spanning the junctions
between the insert and genomic DNA did not indicate signiﬁcant similarities to toxins and allergens.10
3.1.1.3. Information on the expression of the insert11
Protein levels of AAD-12 and PAT were analysed by enzyme-linked immunosorbent assay (ELISA) in
material harvested from ﬁeld trials performed at eight locations in the USA during the 2009 growing
season (also used for comparative assessment, Section 3.2.1). Samples analysed included leaf (V5 and
V10–12), root (R3), forage (R3) and seed (R8-maturity) from soybean DAS-68416-4 treated and not
treated with 2,4-D, glufosinate ammonium-based herbicides or a combination of the two. The mean
values, standard deviations and ranges of protein expression levels of AAD-12 and PAT in seed and
forage are summarised in Table 1.
6 Dossier: Part I – Section D2.
7 Dossier: Part I – Section D2; additional information: 13/4/2012.
8 Guideline for the submission of DNA sequences derived from genetically modiﬁed plants and associated annotations within the
framework of Directive 2001/18/EC and Regulation (EC) No 1829/2003 (http://gmo-crl.jrc.ec.europa.eu/guidancedocs.htm).
9 Dossier: Part I – Section D2; additional information: 13/4/2012, 16/12/2014 and 22/12/2015.
10 Dossier: Part I – Section D2; additional information: 22/12/2015.
11 Dossier: Part I – Section D3.
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3.1.1.4. Inheritance and stability of inserted DNA12
Genetic stability of the soybean DAS-68416-4 insert was assessed by Southern analysis of genomic
DNA from three consecutive generations. The restriction enzyme/probe combinations used were
sufﬁcient to conclude that all the plants tested retained the single copy of the insert and ﬂanking
regions, which were stably inherited in subsequent generations.
Phenotypic stability was observed by segregation analysis of the 2,4-D tolerance trait of soybean DAS-
68416-4. The results supported the presence of a single insertion, segregating in a Mendelian fashion.
3.1.2. Conclusions on molecular characterisation
The molecular characterisation data established that soybean DAS-68416-4 contains a single insert
consisting of one copy of the aad-12 and pat expression cassettes. Bioinformatic analyses of the
sequences encoding the newly expressed proteins and other ORFs present within the insert or
spanning the junctions between the insert and genomic DNA did not indicate signiﬁcant similarities to
toxins and allergens. The levels of the AAD-12 and PAT proteins were obtained and reported
adequately. The stability of the inserted DNA and of the introduced herbicide tolerance traits was
conﬁrmed over several generations.
3.2. Comparative analysis
3.2.1. Evaluation of relevant scientiﬁc data
3.2.1.1. Choice of comparator and production of material for the comparative
assessment13
Application EFSA-GMO-NL-2011-91 presents data on agronomic and phenotypic characteristics, as
well as forage and seed composition, of soybean DAS-68416-4 derived from ﬁeld trials performed at
eight sites in the USA in 2009 (Table 2).
Table 1: Protein expression data (lg/g dry weight) for AAD-12 and PAT in soybean DAS-68416-4
seed and forage
Untreated
Glufosinate
treated
2,4-D treated
Glufosinate and
2,4-D treated
Seed
AAD-12
22.92(a)  4.17(b) 21.67  4.47 20.19  4.16 21.16  4.63
(16.29–32.18)(c) (14.21–31.59) (12.14–29.77) (11.51–31.97)
PAT
2.66  0.46 2.66  0.37 2.57  0.4 2.62  0.44
(1.80–3.71) (1.81–3.52) (1.91–3.34) (1.55–3.41)
Forage
AAD-12
41.95  16.59 46.02  12.73 43.73  13.98 49.32  11.97
(0.56–75.14) (28.35–75.67) (23.63–73.67) (26.78–68.94)
PAT
4.01  0.85 8.28  13.64 4.23  1.01 4.93  0.57
(< 0.06–5.34) (3.46–58.56) (0.42–5.58) (3.04–5.90)
2,4-D: 2,4-dichlorophenoxyacetic acid; AAD-12: aryloxyalkanoate dioxygenase-12; PAT: phosphinothricin acetyltransferase.
Number of seed and forage samples is 28 both for untreated (unsprayed) and for herbicide treated plants.
(a): Mean.
(b): Standard deviation.
(c): Range.
Table 2: Overview of comparative assessment studies with soybean DAS-68416-4 provided in
application EFSA-GMO-NL-2011-91
Study focus Study details Comparators
Commercial reference
varieties
Agronomic and phenotypic
characteristics; composition
Field trials, 2009, USA
(eight locations)
Maverick Six non-GM varieties
Agronomic and phenotypic
characteristics
Seed germination test Maverick None
12 Dossier: Part I – Section D5.
13 Dossier: Part I – Section D7.2.
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The ﬁeld trials were conducted in major soybean growing areas of the USA,14 representing regions of
diverse agronomic practices and environmental conditions. At each site, the following materials were
grown in a randomised complete block design with four replicates: soybean DAS-68416-4 (DAS-68416-4/
untreated), the non-GM comparator Maverick and three non-GM soybean reference varieties, all treated
with required maintenance pesticides (including conventional herbicides); and soybean DAS-68416-4
treated with 2,4-D (DAS-68416-4/2,4-D), with glufosinate ammonium (DAS-68416-4/glufosinate) and
with both 2,4-D and glufosinate ammonium (DAS-68416-4/2,4-D + glufosinate). In total (across sites),
six non-GM soybean reference varieties15 were included in the ﬁeld trials for agronomic/phenotypic
characteristics and composition (Table 2).
Soybean DAS-68416-4 was obtained using the non-GM soybean variety Maverick as recipient
variety (Section 3.1.1.1). As documented by the pedigree, the line of soybean DAS-68416-4 used in
the ﬁeld trials was not crossed with other soybean lines. Maverick was used as comparator in the ﬁeld
trials (Table 2), and has the same genetic background as the line of soybean DAS-68416-4 used. The
GMO Panel considers that this non-GM line is the appropriate conventional counterpart.
Statistical analysis of ﬁeld trials data
The statistical analysis of the agronomic, phenotypic and compositional data from the 2009 ﬁeld
trials followed the recommendations of the GMO Panel (EFSA GMO Panel, 2010b, 2011a). This
included, for each of the four treatments of soybean DAS-68416-4, the application of a difference test
(between the GM soybean and its conventional counterpart) and an equivalence test (between the GM
soybean and the set of non-GM soybean reference varieties). The results of the equivalence test are
categorised into four possible outcomes (I–IV, ranging from equivalence to non-equivalence).16
3.2.1.2. Agronomic and phenotypic analysis17
Agronomic and phenotypic characteristics tested under ﬁeld conditions18
The agronomic and phenotypic parameters evaluated in the 2009 ﬁeld trials were: (early) stand
count, early population (as % planted seeds), days to 50% ﬂowering, days to maturity, plant height,
number of pods, number of seeds, ﬁnal population (plant count), yield, seedling vigour, plant vigour
(crop injury from herbicide application, scored at V4, R1 and R2) and lodging. Additionally, visually
observable responses to naturally occurring diseases (disease incidence) and arthropod damage were
recorded, in order to provide indications of altered stress responses of soybean DAS-68416-4 as
compared with its conventional counterpart.
Of the 16 endpoints evaluated, nine19 could be analysed with the combination of difference and
equivalence testing described in Section 3.2.1.1, with the following results:
• For soybean DAS-68416-4/untreated, the test of difference identiﬁed statistically signiﬁcant
differences from the conventional counterpart for three endpoints (‘number of seeds’, ‘stand
count’ and ‘days to 50% ﬂowering’). The test of equivalence between soybean DAS-68416-4/
untreated and the non-GM soybean reference varieties indicated that ‘number of seeds’ and
‘stand count’ fell under equivalence category I, while ‘days to 50% ﬂowering’20 fell under
equivalence category III (non-equivalence is more likely than equivalence);
• For DAS-68416-4/2,4-D, a statistically signiﬁcant difference was identiﬁed for the endpoint
‘number of seeds’, which fell under equivalence category I;
• For DAS-68416-4/glufosinate, statistically signiﬁcant differences were identiﬁed for ﬁve
endpoints (‘days to maturity’, ‘number of seeds’, ‘stand count’, ‘early population’ and ‘ﬁnal
population’), which all fell under equivalence category I;
• For DAS-68416-4/2,4-D + glufosinate, no statistically signiﬁcant differences were identiﬁed.
14 One site each in Arkansas, Iowa, Indiana and Nebraska, and two sites each in Illinois and Missouri.
15 Pioneer 93M62, LG Seeds C3884N, Arise 9E394, Phillips 363, Hisoy 38C60 and Hoffman H387.
16 In detail, the four outcomes are: category I (indicating full equivalence to the non-GM reference varieties); category II
(equivalence is more likely than non-equivalence); category III (non-equivalence is more likely than equivalence); and
category IV (indicating non-equivalence).
17 Dossier: Part I – Section D7.4; additional information: 18/10/2013 and 2/9/2014.
18 Dossier: Part I – Section D7.4; additional information: 7/8/2012, 27/8/2012, 18/10/2013 and 2/9/2014.
19 The endpoints were: early population, days to 50% ﬂowering, days to maturity, plant height, number of pods, number of
seeds, ﬁnal population, stand count and yield.
20 Soybean DAS-68416-4/untreated: 946.3  30.9 heat units; conventional counterpart: 958.8  30.9 heat units.
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The remaining seven endpoints21 did not fulﬁl the assumptions for parametric testing and were
analysed with the Wilcoxon Signed Rank (WSR) test. Signiﬁcant differences with the conventional
counterpart were identiﬁed for DAS-68416-4/glufosinate (‘plant vigour’ at stage V4) and DAS-68416-4/
2,4-D + glufosinate (‘disease incidence’ and ‘plant lodging’); however, the average values for the GM
soybean were within the range of the non-GM commercial reference varieties.
In conclusion, none of the agronomic and phenotypic differences between soybean DAS-68416-4
and its conventional counterpart observed at ﬁeld level were considered relevant, except for ‘days to
50% ﬂowering’ for soybean DAS-68416-4/untreated. The difference identiﬁed in ‘days to 50%
ﬂowering’ is therefore further assessed for its potential environmental impact in Section 3.4.1.1.
Agronomic and phenotypic characteristics tested under controlled conditions22
Seed germination of soybean DAS-68416-4 was compared with that of its conventional counterpart
under warm and cold conditions. Four replicates of 100 seeds for each line, in a randomised complete
block design, were tested for each of the temperature treatments. The warm treatment consisted of
exposure to a constant temperature of 25°C for 5 days, while the cold treatment consisted of exposure
to 10°C for 7 days, followed by additional exposure to 25°C for 5 days. The germination rate of
soybean DAS-68416-4 seeds under warm and cold conditions did not differ signiﬁcantly from that of its
conventional counterpart.
3.2.1.3. Compositional analysis23
Soybean forage and seeds harvested from the ﬁeld trials in the USA in 2009 were analysed for 87
different constituents (nine in forage24 and 78 in seeds25), including the key constituents
recommended by the OECD (OECD, 2001). Considering the data on substrate speciﬁcity for AAD-12
(Section 3.3.1.2), the GMO Panel concluded that the spectrum of constituents chosen by the applicant
was adequate. Seventeen seed constituents having more than 50% of the observations below the limit
of quantiﬁcation were excluded from the statistical analysis.26
Of the remaining 70 constituents, the test of equivalence could not be applied to a forage endpoint
(NDF) and to ﬁve seed endpoints27 because the estimated variation among the non-GM reference
varieties was too small. Among those six endpoints, only iron level for DAS-68416-4/glufosinate was
signiﬁcantly different from that of the conventional counterpart (Table 3).
The test of difference and the test of equivalence could be applied to the remaining 64 endpoints,
with the following results:
• For soybean DAS-68416-4/untreated, the test of difference identiﬁed statistically signiﬁcant
differences from the conventional counterpart for 22 constituents (2 in forage and 20 in
seeds). The test of equivalence between soybean DAS-68416-4/untreated and the non-GM
soybean reference varieties indicated that the level of 18 of the 22 constituents28 fell under
equivalence category I or II, while the level of four seed constituents fell under equivalence
category III or IV (Table 3).
21 The endpoints were: disease incidence, insect damage, plant lodging, seedling vigour and plant vigour.
22 Additional information: 2/9/2014.
23 Dossier: Part I – Section D7.1; additional information: 13/4/2012, 7/8/2012, 27/8/2012, 18/10/2013, 2/9/2014 and 16/3/2015.
24 Proximates (crude protein, crude fat, ash, and moisture), carbohydrates by calculation, ﬁbre fractions (acid detergent ﬁbre
(ADF) and neutral detergent ﬁbre (NDF)), calcium, and phosphorus.
25 Protein, fat, ash, moisture, carbohydrates, acid detergent ﬁbre (ADF), neutral detergent ﬁbre (NDF), total dietary ﬁbre,
calcium, copper, iron, magnesium, manganese, phosphorus, potassium, sodium, zinc, alanine, arginine, aspartic acid, cystine,
glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan,
tyrosine, valine, caprylic acid (8:0), capric acid (10:0), lauric acid (12:0), myristic acid (14:0), myristoleic acid (14:1),
pentadecanoic acid (15:0), pentadecenoic acid (15:1), palmitic acid (16:0), palmitoleic acid (16:1), heptadecanoic acid (17:0),
heptadecenoic acid (17:1), stearic acid (18:0), oleic acid (18:1), linoleic acid (18:2), linolenic acid (18:3), c-linolenic acid
(18:3), arachidic acid (20:0), eicosenoic acid (20:1), eicosadienoic acid (20:2), eicosatrienoic acid (20:3), arachidonic acid
(20:4), behenic acid (22:0), b-carotene, thiamine HCl, riboﬂavin, niacin, pantothenic acid, pyridoxine HCl, folic acid, ascorbic
acid, a-tocopherol, b-tocopherol, c-tocopherol, d-tocopherol, total tocopherol, total daidzein equivalent, total genistein
equivalent, total glycitein equivalent, lectin (activity), phytic acid, rafﬁnose, stachyose and trypsin inhibitor.
26 These were: sodium, caprylic acid (8:0), capric acid (10:0), lauric acid (12:0), myristic acid (14:0), myristoleic acid (14:1),
pentadecanoic acid (15:0), pentadecenoic acid (15:1), palmitoleic acid (16:1), heptadecanoic acid (17:0), heptadecenoic acid
(17:1), c-linolenic acid (18:3), eicosadienoic acid (20:2), eicosatrienoic acid (20:3), arachidonic acid (20:4), b-carotene and
b-tocopherol.
27 Aspartic acid, proline, serine, NDF and iron.
28 In forage: ash and moisture. In seeds: isoleucine, leucine, methionine, phenylalanine, rafﬁnose, stachyose, oleic (18:1),
linoleic (18:2), linolenic (18:3), arachidic (20:0), ash, moisture, total fat, riboﬂavin, pantothenic acid and folic acid.
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• For DAS-68416-4/2,4-D, statistically signiﬁcant differences were identiﬁed for 23 constituents
(2 in forage and 21 in seeds). The level of 19 of the 23 constituents29 fell under equivalence
category I or II, while the level of four seed constituents fell under equivalence category III or
IV (Table 3).
• For DAS-68416-4/glufosinate, statistically signiﬁcant differences were identiﬁed for 26
constituents (2 in forage and 24 in seeds). The level of 19 of the 26 constituents30 fell under
equivalence category I or II, while the level of seven seed constituents fell under equivalence
category III or IV (Table 3).
• For DAS-68416-4/2,4-D + glufosinate, statistically signiﬁcant differences were identiﬁed for 20
constituents (1 in forage and 19 in seeds). The level of 16 of the 20 constituents31 fell under
equivalence category I or II, while the level of four seed constituents fell under equivalence
category III or IV (Table 3).
Regarding the differences in moisture, stearic acid and calcium and in four amino acids (Table 3),
no further assessment was deemed necessary owing to the known biochemical roles of the
compounds involved and to the small absolute magnitude of the reported changes. The increase in
iron content in DAS-68416-4/glufosinate is not of concern (or beneﬁt), considering the low absorption
of iron (2% to < 5%) from phytate-rich legumes like soybean (Hurrell, 2003). Folic acid decreased in
all GM soybean treatments; however, considering that soybean is not a relevant source of folic acid in
Table 3: Compositional endpoints that are further discussed based on the results of the statistical
analysis: means (for the conventional counterpart and the GM soybean) and equivalence limits
(from the non-GM reference varieties) estimated from the 2009 ﬁeld trials
Endpoint
Conventional
counterpart
Soybean DAS-68416-4 Equivalence
limits from
non-GM
reference
varieties
Untreated(a) 2,4-D(b) Glufosinate(c)
2,4-D +
glufosinate(d)
Moisture(e) (%FW) 13.59 13.22* 12.82* 13.13* 12.74* (12.79, 14.31)
Arginine (%AA) 7.541 7.451* 7.476* 7.466* 7.456* (7.528, 7.840)
Glutamic acid (%AA) 17.03 16.89* 16.92* 16.83* 16.97 (17.02, 17.80)
Histidine (%AA) 2.661 2.711* 2.693 2.653 2.653 (2.507, 2.699)
Leucine (%AA) 7.714 7.755* 7.754* 7.779* 7.762* (7.615, 7.767)
Stearic acid (18:0)
(%FA)
4.457 4.406 4.374* 4.353* 4.29* (3.547, 4.186)
Folic acid (mg/kg DM) 2.772 2.514* 2.53* 2.465* 2.589* (2.477, 3.375)
Lectin activity
(HU/mg protein)
48.21 53.69 65.78* 53.54 56.03* (21.89, 52.77)
Rafﬁnose (%DM) 0.579 0.545* 0.563 0.543* 0.572 (0.544, 0.768)
Calcium (mg/g DM) 2.901 3.253* 3.053* 3.222* 2.999 (2.201, 3.144)
Iron (mg/kg DM) 90.62 102.9 86.95 111.2* 94.01 –
2,4-D: 2,4-dichlorophenoxyacetic acid; FW: fresh weight; DM: dry matter; %AA: percentage of total amino acids; %FA: percentage of
total fatty acids; HU: haemagglutination unit; –: the equivalence test was not applied because the estimated variation among the
non-GM reference varieties was too small.
For the GM soybean, signiﬁcantly different entries are marked with an asterisk, while the outcomes of the test of equivalence are
differentiated by greyscale backgrounds: white (equivalence categories I and II and iron, for which the test was not applied), light grey
(equivalence category III) and dark grey (equivalence category IV).
(a): Sprayed only with conventional herbicides.
(b): Sprayed with 2,4-D.
(c): Sprayed with glufosinate ammonium-based herbicides.
(d): Sprayed with 2,4-D and glufosinate ammonium-based herbicides.
(e): Mean values shown for moisture were re-calculated by EFSA for higher numerical precision.
29 In forage: ash and protein. In seeds: isoleucine, leucine, tryptophan, tyrosine, total glycitein equivalent, oleic (18:1), linoleic
(18:2), linolenic (18:3), arachidic (20:0), eicosenoic (20:1), moisture, protein, total fat, calcium, zinc, pyridoxine HCl and folic
acid.
30 In forage: ash and protein. In seeds: alanine, isoleucine, tryptophan, tyrosine, stachyose, total glycitein equivalent, oleic (18:1),
linoleic (18:2), linolenic (18:3), arachidic (20:0), ash, moisture, protein, total fat, phosphorus, riboﬂavin and pantothenic acid.
31 In forage: ash, protein and phosphorus. In seeds: alanine, isoleucine, leucine, total glycitein equivalent, oleic (18:1), linoleic
(18:2), linolenic (18:3), arachidic (20:0), protein, total fat, riboﬂavin, pantothenic acid and folic acid.
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the human diet, and that animal feed is usually supplemented with folic acid, no concern was
identiﬁed for food and feed safety and nutrition. As rafﬁnose is considered an antinutrient, the
decrease in rafﬁnose observed in two out of four treatments of soybean DAS-68416-4 did not pose
any food/feed safety concern.
Lectin activity32 in soybean DAS-68416-4 was signiﬁcantly different from that in the conventional
counterpart for two of the four treatments (36% higher in DAS-68416-4/2,4-D and 16% higher in
DAS-68416-4/2,4-D + glufosinate) and fell under equivalence category III or IV. Because of the known
antinutritional properties of soybean lectins, the increase in lectin activity is further assessed for
potential impact on food and feed safety in Section 3.3.1.
3.2.2. Conclusions on the comparative analysis
The increase in lectin activity (up to 36%) observed in soybean DAS-68416-4 with respect to its
conventional counterpart is further discussed in Section 3.3.1. The GMO Panel concludes that none of
the other differences identiﬁed in forage and seed composition between soybean DAS-68416-4 and the
conventional counterpart, and none of those identiﬁed in the agronomic and phenotypic
characteristics, needs further assessment regarding food and feed safety.
Based on the tested agronomic and phenotypic characteristics of soybean DAS-68416-4, no
relevant differences were observed between soybean DAS-68416-4 and its conventional counterpart,
except for ‘days to 50% ﬂowering’ for soybean DAS-68416-4 not treated with the intended herbicides.
The difference in ‘days to 50% ﬂowering’ is further assessed for its potential environmental impact in
Section 3.4.1.1.
3.3. Food/feed safety assessment
3.3.1. Evaluation of relevant scientiﬁc data
3.3.1.1. Effects of processing
Processed products
Soybean DAS-68416-4 will undergo existing production processes used for conventional soybean.
No novel production process is envisaged.
Compositional analysis identiﬁed an increase in lectin activity (up to 36%) in DAS-68416-4 seeds
compared to the conventional counterpart. Food/feed processing (e.g. soaking, heating, fermentation)
is known to reduce the content and/or activity of soybean endogenous antinutrients, including lectins
(Liener, 1994; Duranti and Gius, 1997; OECD, 2012). The applicant provided data on toasted meal,
showing that levels of lectin activity in toasted meal from DAS-68416-4 were strongly reduced
compared to those in unprocessed DAS-68416-4 seeds (Table 3).33
Newly expressed proteins
a) Effect of temperature on newly expressed proteins34
The thermal stability of the bacterial AAD-12 protein was evaluated by heating protein solutions for
30 min at 50, 70 and 95°C in a phosphate-based buffer solution. At all heating conditions (50–95°C)
the enzymatic activity was eliminated and the protein lost more than 99% of its immunoreactivity. The
molecular mass (~ 32 kDa) was unchanged. The temperature dependence of bacterial AAD-12 protein
activity was examined after 6 min at different temperatures (1–60°C), using 2,4-D as a substrate,
revealing considerable activity up to 40°C, and signiﬁcantly decreased activity at 50 and 60°C.
The thermal stability of the bacterial PAT protein was evaluated by heating protein solutions for
30 min at different temperatures (25–95°C) in a buffer solution. The molecular mass of the PAT
protein (~ 20 kDa) was unchanged at temperatures ≤ 55°C. At temperatures ≥ 55°C, > 99% of the
enzymatic activity was lost with no residual activity detected above 75°C. At temperatures ≥ 37°C, the
soluble PAT protein lost ≥ 91% of its immunoreactivity.
32 The biological activity of soybean lectins was quantiﬁed using a haemagglutination assay with rabbit red blood cells (RBCs)
(Liener, 1955). The activity was measured in haemagglutination units (HU): one HU corresponds to the level of test solution
(serially diluted) that gives agglutination of 50% of the RBCs.
33 Dossier: Part I – Section D7.10.2; additional information: 29/4/2016.
34 Dossier: Part I – Section D7.8.1; additional information: 18/10/2013.
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b) Effect of pH on newly expressed proteins35
The effect of pH on the in vitro activity of the bacterial AAD-12 was assessed using 2,4-D as a
substrate and a mixed buffer system with pH varying from 5.5 to 9.5. Considerable activity after 6 min
was observed over a narrow window, between pH 6 and 7.5 with an optimum at 7.
The effect of pH on the in vitro activity of the bacterial PAT was assessed using acetyl-CoA and
glufosinate as substrates and a mixed buffer system with pH at 3, 8 and 11. The enzyme activity was
signiﬁcantly reduced after 10 min, at pH 3 and 11, showing highest activity at pH 8; the molecular
mass (~ 20 kDa) was unchanged at acidic, neutral, and basic pH’s.
3.3.1.2. Toxicology
Soybean DAS-68416-4 expresses two new proteins, AAD-12 and PAT (see Section 3.1.1).
Proteins used for safety assessment
Given the technical restraints in producing large enough quantities of the proteins from plants for
safety testing, these proteins were recombinantly produced in Pseudomonas ﬂuorescens. Prior to
safety studies, a set of biochemical methods was employed to demonstrate the equivalence between
soybean- and microbe-derived proteins. Puriﬁed proteins from these two sources were characterised
and compared in terms of their physicochemical, structural and functional properties.
a) AAD-12 characterisation and equivalence36
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and western blot analysis
showed that plant- and microbe-derived AAD-12 proteins had the expected molecular weight of ~ 32 kDa
and were comparably immunoreactive to AAD-12 protein speciﬁc antibodies. In addition, glycosylation
detection analysis demonstrated that the AAD-12 proteins were not glycosylated. Amino acid sequence
analysis by mass spectrometry methods showed that both proteins matched their expected sequence.
These data also showed that the N-terminal methionine of both proteins was truncated, while alanine 2 of
the plant protein was also acetylated. Additional variants of the plant protein were identiﬁed that were
truncated up to threonine 9. Such modiﬁcations are common in eukaryotic proteins (e.g. Polevoda and
Sherman, 2000). The C-termini of the plant- and microbial-derived proteins were identical and fully
matched the theoretical AAD-12 sequence. Functional equivalence was demonstrated by a biochemical
in vitro activity assay which showed that both proteins had comparable activity for the intended herbicide.
Plant- and microbial-produced AAD-12 proteins were also screened for their ability to utilise certain
endogenous plant substrates and none of them were metabolised by AAD-12.
b) PAT characterisation and equivalence37
The equivalence between the plant- and microbe-derived PAT proteins was demonstrated by SDS-
PAGE and western blot analysis. The results from these analyses showed that both proteins migrated
to the expected molecular weight of ~ 20.5 kDa. In addition, western blot analysis showed that both
proteins were comparably immunoreactive to PAT speciﬁc antibodies. Functional equivalence was
demonstrated by a biochemical in vitro activity assay which showed that both proteins had comparable
activity for the intended herbicide.
The protein characterisation data comparing the structural, biochemical and functional properties of
plant- and microbial-derived AAD-12 and PAT proteins indicate that these proteins are equivalent.
Therefore, the GMO Panel accepts the use of the AAD-12 and PAT proteins expressed in bacteria for
the safety studies.
Toxicological assessment of newly expressed proteins
The PAT protein has been previously assessed by the GMO Panel (e.g. EFSA 2007; EFSA GMO
Panel, 2011c, 2013a,b), and no safety concerns for humans and animals were identiﬁed. Updated
bioinformatics analyses did not reveal similarities of the PAT protein to known toxins.38 The GMO
Panel is not aware of any new information that would change these conclusions. The GMO
Panel concludes that the PAT protein does not raise safety concerns.
35 Additional information: 18/10/2013.
36 Dossier: Part I – Section D7.8.1; additional information: 12/3/2012, 11/6/2015 and 13/5/2016.
37 Dossier: Part I – Section D7.8.1; additional information: 13/5/2016.
38 Dossier: Part I – Section D7.8.1; additional information: 18/10/2013, 2/9/2014 and 22/12/2015.
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The newly expressed AAD-12 protein is assessed below.
a) Bioinformatic studies38
Bioinformatic analysis of the amino acid sequence of the AAD-12 protein expressed in DAS-68416-4
soybean revealed no relevant similarities to known toxic proteins (Section 3.1.1.2).
b) In vitro degradation studies39
The resistance to degradation by pepsin of the bacterial AAD-12 and PAT proteins was investigated
in solutions at pH ~ 1.2 in two independent studies. The integrity of the test proteins in probes taken
at various time points was analysed by SDS-PAGE followed by protein staining or western blot. The
AAD-12 protein was degraded by pepsin within 30 s. The PAT protein was degraded by pepsin within
1 min.
c) Acute oral toxicity testing
The bacterial AAD-12 protein was administered by oral gavage at a dose of 2,000 mg/kg body
weight (bw) to male and female Crl:CD1(ICR) mice. No adverse effects related to the AAD-12 protein
were observed.40
A bacterial PAT protein was administered by oral gavage at a dose of 5,000 mg/kg bw to male and
female Crl:CD1 mice. No adverse effects related to the PAT protein were observed.41
The GMO Panel is of the opinion that acute toxicity testing of the newly expressed proteins is of
little additional value for the risk assessment of the repeated consumption of food and feed from GM
plants by humans and animals.
d) 28-Day repeated dose toxicity study
The applicant provided a 28-day oral repeated dose toxicity study in mice40 to investigate the
potential toxicity of the AAD-12 protein. However, the GMO Panel did not consider the overall study
design adequate to identify the potential hazard of the AAD-12 protein, because of the low doses of
AAD-12 protein tested (highest target dose level approximately 47 mg/kg bw per day, corresponding
to an actual dose of approximately 17 mg/kg bw per day) and the limited number of animals used in
treatment groups (5 per sex per group) which is not considered sufﬁcient to obtain an adequate
statistical power (EFSA GMO Panel, 2011a).
The GMO Panel requested another 28-day oral repeated dose toxicity study in rodents, to support
the safety assessment of the AAD-12 protein, with a sufﬁcient number of animals to obtain an
adequate statistical power, selecting the doses according to OECD TG 40742 in order to induce adverse
effects at the highest dose, or following a limit test approach if toxicity is not expected. In the second
28-day repeated dose toxicity study using mice,43 the number of animals per treatment group was in
line with EFSA GMO Panel (2011a), but the highest target dose selected (142 mg/kg bw per day) was
too low for an adequate hazard identiﬁcation, as also was the case in the ﬁrst 28-day study submitted
by the applicant. Therefore, the GMO Panel did not consider this study in the risk assessment. The
study was withdrawn by the applicant.44
The applicant provided a new 28-day oral repeated dose toxicity study in mice,45 which was
conducted in accordance with OECD TG 407 and in compliance with the principles of Good Laboratory
Practice (GLP). Groups of singly caged Crl:CD1(ICR) mice (11 per sex per group, approximately 8
weeks old at study start) were administered by gavage the AAD-12 protein (in 0.5% METHOCELTM) at
a targeted nominal dose of 1,100 mg/kg bw per day (AAD-12 protein group), the vehicle alone
(vehicle control group), or bovine serum albumin (BSA) at a targeted nominal dose of 1,100 mg/kg bw
per day (BSA control group).
39 Dossier: Part I – Section D7.9.1; additional information: 18/10/2013 and 2/9/2014.
40 Dossier: Part I – Section D7.8.1.
41 Dossier: Part I – Section D7.8.1; additional information: 19/2/2015. The bacterial recombinant expression system was not
speciﬁed in the study report.
42 OECD (Organisation for Economic Co-operation and Development), Test No. 407: Repeated Dose 28-day Oral Toxicity Study in
Rodents. OECD Guidelines for the Testing of Chemicals, Section 4.
43 Additional information: 23/11/2015 and 13/5/2016.
44 Applicant to EFSA letter – 2/3/2016.
45 Additional information: 13/5/2016.
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The ADD-12 protein and BSA protein dosing formulations were prepared daily. Samples of the ADD-
12 protein and BSA protein dosing formulations along with vehicle were taken from the ﬁrst mix, from
a mix near the middle, and from a mix towards the end of the study for dose conﬁrmation and
homogeneity analyses.
Feed and water were provided ad libitum. During the treatment period, the animals were checked
daily for mortality and general clinical signs. Detailed clinical observations were conducted on all
animals pretreatment and then weekly. Ophthalmoscopy was carried out before the start and at the
end of the treatment period. Body weights were recorded on test days 1, 2, 3, 4, 8, 15, 22 and 29
(terminal body weight) and body weight gains were calculated relative to test day 1. Feed
consumption was determined on test days 1–2, 2–3, 3–4, 4–8, 8–15, and 22–29. At the end of the
treatment period, blood samples were taken and haematological, coagulation and clinical chemistry
analyses were performed. All animals were sacriﬁced and underwent a detailed necropsy examination
with selected organs weighed. Organs and tissues from all animals were subjected to a comprehensive
histological examination.
The GMO Panel noted that the AAD-12 protein formulations were prepared daily from the
powdered test material stored at approximately 4°C until use. Stability tests on the powdered test
material (i.e. the lyophilised AAD-12 protein) were not performed as part of this study. According to
the study report,45 the lyophilised AAD-12 protein was determined to be stable for 81 months under
refrigerated storage conditions, as part of previous studies45; however, the GMO Panel noted that
stability of the AAD-12 protein was not documented in these previous studies. Therefore, the
concentration of AAD-12 protein of 33.1% in the powdered test material following storage has not
been conﬁrmed. However, as dose conﬁrmation analyses were performed on the dosing formulations
both at the start and towards the end of the study, the GMO Panel considered that this is not a major
limitation compromising the 28-day study.
The GMO Panel noted that haematology and clinical chemistry analyses were conducted on six
mice/gender per group and coagulation (prothrombin time) was conducted on the remaining ﬁve
animals in each group. The reasoning provided by the applicant was practical limitations in obtaining
sufﬁcient quantities of blood from mice for haematology and clinical chemistry, and coagulation
examinations in the same animal. However, it is well known that when mice are used as the test
animal, additional animals may be needed in each dose group to conduct all required determinations.
The GMO Panel also noted that the animals were not fasted prior to necropsy and blood collection, as
recommended in OECD TG 407.
The AAD-12 protein group was statistically compared to the BSA control group; the latter was also
compared to the vehicle control group in order to assess potential effects of the higher protein intake.
For all the continuous parameters a two-way analysis of variance (ANOVA; factors: sex and dose) for
the two sexes combined, in order to account for sex-dose interactions, and a one-way ANOVA (factor:
dose) separately for each sex were performed. For all parameters, in case a statistically signiﬁcant
dose effect was found with the one- or two-way ANOVA, each individual dose group was compared to
the control group using Dunnett’s test. For body weight gains, globulin, albumin/globulin ratio, red
blood cell (RBC) indices, and differential white blood cell (WBC) counts only descriptive statistics were
reported.
The results of the dose conﬁrmation analyses revealed that the average recoveries for AAD-12 and
BSA protein in 0.5% METHOCELTM were 71.7% and 73.2%, respectively, based on nominal dosing
suspensions at 110 mg/ml. The average recoveries were therefore within the acceptable experimental
variation (70–120%). The GMO Panel noted that based on the measured concentration of AAD-12
protein in the dosing suspension, the actual dose administered was 789 mg/kg bw per day. The results
of the homogeneity analyses indicated that the preparations were homogeneously mixed.
The few statistically signiﬁcant differences between the BSA control and vehicle control groups in
the examined parameters were considered by the GMO Panel to be within normal biological variability;
therefore, both the vehicle control and the BSA control groups were considered suitable to be used as
the control groups for the comparison and evaluation of data from the AAD-12 protein group.
No mortality occurred during the treatment period. The GMO Panel considered that the isolated
clinical ﬁndings and the few ophthalmic changes observed at the end of the study in the AAD-12
protein group were not treatment-related.
No statistically signiﬁcant differences in body weight or body weight gain were observed in the
AAD-12 protein group compared to the BSA control group.
In comparison with the BSA control group, males of the AAD-12 protein group showed statistically
signiﬁcantly lower feed consumption during speciﬁc time periods (days 1–2, 2–3, 15–22, 22–29); these
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differences were not considered as an adverse treatment-related effect by the GMO Panel as there
were no statistically signiﬁcant differences in body weights and body weight gains in animals of the
AAD-12 protein group when compared with the BSA control group.
Haematology analysis showed statistically signiﬁcantly higher WBC in males of the AAD-12 protein
group when compared with the BSA control group. This ﬁnding was largely due to changes in two
individual animals (one with an abscess in the neck region and a granulomatous inﬂammation around
the oesophagus; the other showed chronic inﬂammation of the mediastinal tissue). The changes which
largely resulted from (not signiﬁcantly) higher values in neutrophil counts46 were attributed by the
applicant to inadvertent trauma associated with repeated oral gavage and not to treatment with the
AAD-12 protein. The GMO Panel agrees with the interpretation by the applicant.
The platelet (PLT) count in males treated with the AAD-12 protein was statistically signiﬁcantly
higher compared with the BSA control group. This ﬁnding was, according to the applicant,46 attributed
to one animal with inadvertent trauma (abscess in the neck region and a granulomatous inﬂammation
around the oesophagus) related to repeated oral gavaging procedure and not related to the treatment
with the AAD-12 protein. After removing this animal from the statistical analysis, the increase in the
PLT count showed no statistical signiﬁcance. The increase was considered by the applicant not to be
related to the treatment with the AAD-12 protein. The GMO Panel noted that even after removing this
single animal with the highest PLT count (1,836 9 103/lL) the mean PLT count in the male AAD-12
protein group (1,499 9 103/lL vs 1,555 9 103/lL) was still higher compared to both the BSA protein
group (1,321 9 103/lL) and the vehicle control group (1,302 9 103/lL). The GMO Panel could not
exclude that the increased PLT count was related to the treatment with the ADD-12 protein for the
following reasons: (1) the PLT counts for the individual animals in the male AAD-12 protein group
(range 1,386–1,836 9 103/lL) were either comparable to or higher than the two highest PLT counts
for individual animals in the BSA protein group (1,454 and 1,510 9 103/lL) and the vehicle control
group (1,398 and 1,511 9 103/lL); (2) the SD (87) for the AAD-12 protein group after removing the
single animal with the highest PLT count was lower than that for the control groups (BSA protein: 168,
vehicle control: 143); and (3) the PLT counts for ﬁve out of six of the individual animals in the male
AAD-12 protein group (range 1,466–1,836 9 103/lL) were higher than the historical control range
(1,205–1,417 9 103/lL) presented in the study report (ﬁve studies between 2012 and 2016).
However, as the increase was slight and not statistically signiﬁcant after removing the single animal
with the highest PLT count the GMO Panel considered that this difference was not toxicologically
relevant.
In females treated with the AAD-12 protein, the reticulocyte count (RET) was slightly, but
statistically signiﬁcantly lower compared with the BSA control group; the mean value was very close to
that of the vehicle control group and within the historical control range. This difference was not
considered to be toxicologically relevant by the GMO Panel as there were no differences in related
haematological parameters.
There were no other signiﬁcant differences in haematological and clinical chemistry parameters, or
in the prothrombin time. However, the GMO Panel noted that the haematological, clinical chemistry
and coagulation examinations were only performed on six or ﬁve animals per gender per group, and
thus, the GMO Panel recommendation to use a higher number of animals (EFSA GMO Panel, 2011a)
was not fulﬁlled for the examination of these parameters.
Organ weight determinations showed no statistically signiﬁcant differences except for a lower
absolute (but not relative) epididymides weight (7.6%) in males treated with the ADD-12 protein
compared with the BSA control group. This difference was not considered as toxicologically relevant by
the GMO Panel as there was no difference in the relative epididymides weight.
Macroscopic examinations at necropsy revealed no gross pathological ﬁndings related to the
treatment with the AAD-12 protein. Microscopic examinations of selected organs and tissues identiﬁed
no treatment-related differences in the incidences and severity of the histopathological ﬁndings
between the groups.
The GMO Panel noted that the haematological, clinical chemistry and coagulation examinations
were only performed on six or ﬁve animals per gender per group (in line with OECD TG 407 minimum
requirements), and thus, the GMO Panel recommendation to use a higher number of animals to ensure
appropriate statistical power (EFSA GMO Panel, 2011a) was not fulﬁlled for the examination of these
parameters. Nevertheless, the GMO Panel concluded that no adverse effects were observed in this
46 Additional information: 26/10/2016.
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study after a 28-day administration of the AAD-12 protein to mice at the dose tested (789 mg/kg bw
per day).
Toxicological assessment of components other than newly expressed proteins
No new constituents other than the AAD-12 and PAT proteins are expressed in soybean DAS-68416-4.
With the exception of an increased lectin activity (up to 36%) in soybean DAS-68416-4 for two out
of four treatments, no relevant changes in the composition of the GM soybean were detected in the
comparative compositional analysis (Table 3).
Lectins are a superfamily of proteins selectively binding carbohydrates, and function as recognition
molecules in cell–molecule and cell–cell interactions in a variety of biological systems (Sharon and Lis,
2004; Miyake et al., 2007). Lectins are natural components in plants used for food and feed (Nachbar
and Oppenheim, 1980; Peumans and Van Damme, 1996; Vasconcelos and Oliveira, 2004) and are
widely distributed among Leguminosae, including soybean (Gupta, 1987). The ingestion of legumes
containing high levels of certain lectins may be associated with gastrointestinal effects in humans and
animals (Noah et al., 1980; Rodhouse et al., 1990; Bardocz et al., 1995; Grant et al., 1995).
In its toxicological assessment of the increase in lectin activity, the GMO Panel took into account the
following:
1) The toxicity of raw soybean lectins is low compared to other commonly consumed legumes
(Nasi et al., 2009), consisting of reduced growth performance and transient small intestine
hypertrophy in experimental feeding studies (Grant et al., 1995).
2) Current industrial and traditional home processing practices are known to considerably
reduce lectin content and/or activity in legumes, including soybean (Liener, 1994; Duranti
and Gius, 1997; OECD, 2012), and the safe use of soybean depends on such practices
(K€onig et al., 2004). However, it cannot be excluded that residual lectin activity is still
present in processed soybean products (Peumans and Van Damme, 1996; Rizzi et al., 2003;
Vasconcelos and Oliveira, 2004).
3) The observed increase was considered in the context of the high variability reported for lectin
activity and lectin protein content in raw soybean (Becker-Ritt et al., 2004; OECD, 2012; Maria
John et al., 2017). Regarding any possible impact of the observed increase on the levels of
residual activity in processed products, it was considered that (measurable) residual activity is
also characterised by high variability (across different products (Calderon de la Barca et al.,
1991) and between different samples of the same product (Maenz et al., 1999)).
Based on these considerations, the GMO Panel is of the opinion that the observed increase (up to
36%) in lectin activity in raw soybean DAS-68416-4 is unlikely to raise additional toxicological concerns
for soybean DAS-68416-4 with respect to conventional soybean varieties.
The nutritional impact of the increase in lectin activity in soybean DAS-68416-4 will be discussed in
Section 3.3.1.5.
3.3.1.3. Animal studies with the food/feed derived from GM plants
The applicant provided a 42-day feeding study with a total of 600 (half male and half female)
chickens for fattening (day-old Ross 708).47 The birds were randomly allocated to ﬁve dietary
treatment groups with 120 chicks per treatment (12 pens per treatment, six pens for male and six for
female, ten birds per pen). Birds fed diets containing soybean DAS-68416-4 (veriﬁed by PCR) were
compared to those fed diets containing the conventional counterpart (control) or each of three non-GM
commercial soybean varieties (LG C3540, Pioneer 93B82 and HiSoy 38C60). The starter (1–14 days),
grower (15–28 days) and ﬁnisher (29–42 days) diets consisted of 40.4%, 36.4% and 31.5% soybean
meal, respectively. The main other component was a commercial corn meal. Before feed formulation,
all soybean varieties were analysed for proximates, ﬁbre fractions, isoﬂavones, minerals, amino acids,
antinutrients and mycotoxins. The metabolisable energy was calculated for each maize grain source. All
diets were balanced for metabolisable energy, crude protein and amino acids. Feed in mash form and
water were provided to the birds for ad libitum intake. The presence of AAD-12 and PAT proteins was
conﬁrmed analytically in unprocessed seeds and toasted meal. Chickens were observed twice daily for
clinical signs; deaths were recorded and necropsy performed in all cases. Body weight and feed intake
were measured on days 1, 14, 28 and 42. At the end of the study, four birds per pen were taken for
carcass evaluation (yield, dressing percentage, weight of thighs, breast, wings, legs, abdominal fat and
47 Dossier: Part I – Section D7.10.2.
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whole liver). ANOVA (pen was considered as the experimental unit, dietary treatment and gender as
ﬁxed factors) was applied for statistical evaluation. Four pairwise comparisons between the GM group
and each of the non-GM groups were made using Dunnett’s test. Overall mortality was low (2.3%) with
no signiﬁcant difference between the groups. Signiﬁcant treatment-by-sex interactions were detected
for ﬁnal weight, daily gain and daily feed intake. No signiﬁcant differences between the GM group and
the control group were detected within genders for ﬁnal weight and daily gain, except for daily feed
intake. Feed:gain ratio showed similar differences (average 1.57 for females and 1.47 for males).
Carcass characteristics and liver weight did not show signiﬁcant differences between the GM and the
control group; signiﬁcantly higher relative breast weight was found in birds fed diets containing one of
the commercial varieties; and relative higher thigh weight was found in birds fed diets containing
another commercial variety.
The GMO Panel concludes that administration of diets containing up to 40.4% soybean DAS-68416-4
to broilers, up to 42 days, did not cause adverse effects. Moreover, the measured performance
endpoints were similar between groups fed balanced diets containing GM and non-GM soybean.
3.3.1.4. Allergenicity
The strategies to assess the potential risk of allergenicity focus on the source of the recombinant
protein, on the potential of the newly expressed protein to induce sensitisation or to elicit allergic
reactions in already sensitised persons and on whether the transformation may have altered the
allergenic properties of the modiﬁed plant.
Assessment of allergenicity of the newly expressed proteins48
A weight-of-evidence approach was followed, taking into account all of the information obtained on
the newly expressed proteins, as no single piece of information or experimental method yield sufﬁcient
evidence to predict allergenicity (EFSA, 2006a; Codex Alimentarius, 2009; EFSA GMO Panel, 2010c).
The aad-12 gene originates from D. acidovorans and the pat gene originates from
S. viridochromogenes, microorganisms which are not considered to be common allergenic sources.
Updated bioinformatic analyses of the amino acid sequences of the AAD-12 and PAT proteins, using
the criterion of 35% identity in a sliding window of 80 amino acids, revealed no signiﬁcant similarities
to known allergens. In addition, the applicant also performed analyses searching for matches of eight
contiguous identical amino acid sequences between the AAD-12 and PAT proteins and known
allergens, which conﬁrmed the outcome of the previous bioinformatic analysis.
The study on resistance to degradation of the AAD-12 and the PAT proteins by pepsin has been
described in Section 3.3.1.2.b.
The GMO Panel has previously evaluated the safety of the PAT protein in the context of several
other applications and no concerns about allergenicity were identiﬁed (e.g. EFSA 2007; EFSA GMO
Panel, 2011c, 2013a,b).
There is no information available on the structure or function of the newly expressed AAD-12 and
PAT proteins that would suggest an adjuvant effect of the individual proteins or their simultaneous
presence in soybean DAS-68416-4 resulting in or increasing an eventual speciﬁc immunoglobulin E
(IgE) response to a bystander protein.
In the context of the present application, the GMO Panel considers that there are no indications
that the newly expressed AAD-12 and PAT proteins, individually or simultaneously present, in soybean
DAS-68416-4 may be allergenic.
Assessment of allergenicity of the whole GM plant or crop49
Soybean is considered to be a common allergenic food (OECD, 2012).50 Therefore, any potential
change in the endogenous allergenicity of the GM plant when compared with that of the conventional
non-GM variety should be assessed in line with the applicable GMO Panel guidance document (EFSA,
2006a). The applicant performed in vitro allergenicity studies with extracts of soybeans DAS-68416-4,
its conventional counterpart (Maverick) and three non-GM commercial soybean varieties.
Speciﬁcally, the applicant performed two-dimensional (2D) electrophoresis of extracts of soybean
DAS-68416-4 and its conventional counterpart followed by western blotting using individual sera from
48 Dossier: Part I – Section D7.9.1; additional information: 18/10/2013, 2/9/2014 and 22/12/2015.
49 Dossier: Part I – Section D7.9.2.
50 Directive 2007/68/EC of the European Parliament and of the Council of 27 November 2007 amending Annex IIIa to Directive
2000/13/EC of the European Parliament and of the Council as regards certain food ingredients. OJ L 310, 27.11.2007, p. 11–14.
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six allergic humans to soybean. In addition, immunoglobulin E (IgE) inhibition ELISA studies using
individual sera from four allergic humans to soybean were also carried out. These studies showed no
meaningful differences in the IgE-binding patterns between the extracts of proteins derived from
soybean DAS-68416-4 and its conventional counterpart.
The applicant also performed one-dimensional (1D) electrophoresis of extracts of soybean DAS-
68416-4, its conventional counterpart and three commercial non-GM soybean varieties followed by
western blot analysis using individual as well as pooled sera from 20 individuals allergic to soybean.
Inhibition ELISA studies were also carried out using pooled sera from 20 individuals allergic to
soybean. The GMO Panel has previously indicated the limitations of the 1D-PAGE gels and the use of
pooled sera for the allergenicity assessment (see Annex 4 and Annex 5 of EFSA GMO Panel, 2010c).
In the context of this application and considering the information above, the GMO Panel is of the
opinion that there is no evidence that the genetic modiﬁcation might signiﬁcantly change the overall
allergenicity of soybean DAS-68416-4 when compared with that of its conventional counterpart.
3.3.1.5. Nutritional assessment of GM food/feed
Comparison of the composition of soybean DAS-68416-4 with its conventional counterpart and non-
GM reference varieties identiﬁed differences in the lectin activity in seeds (up to 36% increase in the
GM soybean, Table 3). Lectins are known to be antinutritional factors for humans and animals
(Section 3.3.1.2).
The presence of lectins in common plant foods, such as Leguminosae, is well known (Vasconcelos
and Oliveira, 2004; Peumans and Van Damme, 1996). Current industrial and traditional home
processing practices are used to considerably reduce lectin content and/or activity in legumes,
including soybean (Liener, 1994; Duranti and Gius, 1997; OECD, 2012). It cannot be excluded that
residual lectin activity is still present in processed soybean food products (Calderon de la Barca et al.,
1991; Peumans and Van Damme, 1996; Rizzi et al., 2003); hence, dietary exposure to functionally
active lectins at residual levels in processed products is considered a common event (Nachbar and
Oppenheim, 1980; Vasconcelos and Oliveira, 2004).
Soybean oil is the predominant soybean product for human consumption. The oil is obtained by
fractionation of soybean seeds and is almost entirely composed of fat, with a negligible non-fat
fraction (0.3%) consisting of moisture, insoluble, and volatile matter (Gandhi, 2009).51 Even in the
worst-case scenario, assuming that the entire non-fat fraction of the oil derived from soybean
DAS68416-4 are lectins, the observed increase in lectin activity in soybean DAS-68416-4 (up to 36%)
would not raise concerns compared to oil from non-GM soybeans. Other processing procedures, such
as soaking, heating and fermentation, are known to considerably reduce active lectin content in
soybean (Gupta, 1987; Codex Alimentarius, 1989, 2013, 2015; Reddy and Pearson, 1994; Duranti and
Gius, 1997; Lajolo and Genovese, 2002; OECD, 2012). Soybean sprouting is also known to be
accompanied by a considerable decrease in active lectin content (Rizzi et al., 2003). In the context of
this application, it was also demonstrated that toasting is effective in lowering lectin activity of DAS-
68416-4 soybean seeds to negligible levels.47 The GMO Panel considers that the additional intake of
active lectins from soybean DAS-68416-4 food products (deriving from the 36% increase in the raw
material) is likely to be negligible compared to the habitual dietary intake of lectins from non-GM
soybean food products.
Soybean meal is the by-product of the extraction of soybean oil and it is the most important protein
source used to feed farm animals. In the solvent extraction process, the soybeans are cracked, heated
and ﬂaked, and the oil is extracted by solvent (usually hexane). The obtained by-product is then
subjected to treatments that improve its nutritional value by a decrease in the activity of antinutritional
factors (e.g. lectins and enzyme inhibitors). Current conditions during the commercial processing of
soybean into commodity oil, meal and other products, and on-farm processing conditions (e.g.
soaking, roasting, extrusion and micronisation) have consistently shown the ability to reduce the
presence and/or activity of lectins and enzyme inhibitors to the extent that they can be consumed by
monogastric animals. Quality processes and testing such as urease activity are in place, mainly in the
commercial production, to assure that many of these commercial products have undergone the proper
processing procedures for use in feed applications.52 Urease activity is highly positively correlated with
lectin and trypsin inhibitor activity (Fasina et al., 2003). The GMO Panel considers that, within the
51 Additional information: 29/4/2016.
52 Commission Regulation (EU) No 68/2013, on the Catalogue of feed materials http://eur-lex.europa.eu/legal-content/EN/TXT/
PDF/?uri=CELEX:32013R0068&from=EN
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frame of good farming practices described above and considering current processing practices, the
observed increase in lectin activity is unlikely to inﬂuence animal nutrition.
The GMO Panel concluded that food and feed derived from soybean DAS-68416-4 are expected to
have no adverse nutritional impact, as compared to those from its conventional counterpart and
commercial non-GM reference varieties.
3.3.1.6. Post-market monitoring of GM food/feed
There was no indication that food/feed products derived from soybean DAS-68416-4 are less safe
or nutritious than those derived from its conventional counterpart or the non-GM commercial varieties
(Sections 3.2.1.3, 3.3.1.2 and 3.3.1.5). Therefore, in line with EFSA (2006a) and EFSA GMO
Panel (2011a), the GMO Panel is of the opinion that post-market monitoring of the GM food/feed is
unnecessary.
3.3.2. Conclusions on the food/feed safety assessment
The safety assessment identiﬁed no concerns regarding the potential toxicity of the AAD-12 and
PAT proteins newly expressed in soybean DAS-68416-4, considering their structural and functional
properties, the results of bioinformatic analyses and the results of a sub-acute 28-day toxicity study on
AAD-12. The GMO Panel did not identify indications of safety concerns regarding allergenicity or
adjuvanticity with the AAD-12 and PAT proteins or regarding the overall allergenicity of DAS-68416-4.
The observed increase in lectin activity in raw soybean DAS-68416-4 is unlikely to raise additional
concerns for food/feed safety and nutrition for the GM soybean as compared to its conventional
counterpart and the non-GM commercial varieties. No other changes in soybean DAS-68416-4
composition relevant for food/feed safety and nutrition were identiﬁed. Considering current soybean
processing, soybean DAS-68416-4 is as safe and nutritious as its conventional counterpart and the
non-GM commercial varieties.
3.4. Environmental risk assessment and monitoring plan
3.4.1. Evaluation of relevant scientiﬁc data
Considering the scope of the application EFSA-GMO-NL-2011-91 (which excludes cultivation), the
ERA of soybean DAS-68416-4 is mainly concerned with: (1) the exposure of bacteria to recombinant
DNA in the gastrointestinal tract of animals fed GM material and bacteria present in environments
exposed to their faecal material (manure and faeces), and (2) the accidental release into the
environment of viable soybean DAS-68416-4 seeds during transportation and/or processing (EFSA
GMO Panel, 2010a).
3.4.1.1. Environmental risk assessment
Persistence and invasiveness of the GM plant53
Cultivated soybean (G. max (L.) Merr.) is a species in the subgenus Soja of the genus Glycine. The
species originated from eastern Asia and is a highly domesticated crop (Lu, 2005). Cultivated soybean
seeds rarely display any dormancy characteristics and can grow as volunteers in the year after
cultivation only under certain environmental conditions. If volunteers occur, they do not compete well
with the succeeding crop, and can easily be controlled mechanically or chemically (OECD, 2000). The
presence of volunteers of G. max was occasionally reported in some areas of Italy where soybean is
intensively cultivated (Celesti-Grapow et al., 2010). However, soybean seeds usually do not survive
during the winter owing to herbivory, rotting and germination, or owing to management practices prior
to planting the subsequent crop (Owen, 2005). Also, survival of soybean plants outside cultivation
areas is limited mainly by a combination of low competitiveness, absence of a dormancy phase, and
susceptibility to plant pathogens and cold climatic conditions.
The applicant presented agronomic and phenotypic data on soybean DAS-68416-4 gathered from
ﬁeld trials conducted in soybean growing areas in the USA (Table 2). The data showed a statistically
signiﬁcant reduction in ‘days to 50% ﬂowering’, for which non-equivalence between soybean DAS-
68416-4/untreated and the non-GM soybean reference varieties was more likely than equivalence. No
relevant differences in the other measured plant characteristics were identiﬁed (Section 3.2.1.2). Due
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to the low survival capacity of soybean, the observed difference in ‘days to 50% ﬂowering’ is unlikely
to change the ﬁtness (e.g. survival, fecundity, competitiveness) or invasiveness characteristics of
soybean DAS-68416-4 plants.
As the general characteristics of soybean DAS-68416-4 remain unchanged compared to its
conventional counterpart, it is considered very unlikely that soybean DAS-68416-4 will differ from
conventional soybean varieties in its ability to survive until subsequent seasons, or to establish
occasional feral plants under European environmental conditions in case of accidental release into the
environment of viable soybean DAS-81419-2 seeds during transportation and processing.
The GMO Panel is not aware of any scientiﬁc report of increased survival capacity, including
overwintering, of existing GM soybeans varieties (Dorokhov et al., 2004; Owen, 2005; Bagavathiannan
and Van Acker, 2008; Lee et al., 2009). Therefore, the GMO Panel is of the opinion that the likelihood
of environmental effects of occasional feral soybean DAS-68416-4 plants in Europe will not be different
from that of conventional soybean varieties.
Effects of gene transfer54
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic
material, either through horizontal gene transfer of DNA, or through vertical gene ﬂow via cross-
pollination from feral plants originating from spilled seed.
1) Plant-to-bacteria gene transfer54
Genomic DNA is a component of many food and feed products derived from soybean. It is well
documented that DNA present in food and feed becomes substantially degraded during processing and
digestion in the human or animal gastrointestinal tract. However, a low level of exposure of fragments
of ingested DNA, including the recombinant fraction of such DNA, to bacteria in the digestive tract of
humans, domesticated animals, and other environments exposed to the GM plant or plant material is
expected.
Current scientiﬁc knowledge of recombination processes in bacteria suggests that horizontal
transfer of non-mobile, chromosomally located DNA fragments between unrelated organisms (such as
from plants to bacteria) is not likely to occur at detectable frequencies under natural conditions (for
further details, see EFSA, 2009).
A successful horizontal gene transfer would require stable insertion of the recombinant DNA
sequences into a bacterial genome and a selective advantage to be conferred to the transformed host.
The only mechanism known to facilitate horizontal transfer of non-mobile, chromosomal DNA
fragments to bacterial genomes is homologous recombination. This requires the presence of stretches
of DNA sequences that are similar in the recombining DNA molecules. The similarity between the plant
and bacterial sequences can be situated in the coding region of a recombinant protein (transgene), or
in the border regions of the recombinant gene cassettes inserted into the plant genome. In the case of
sequence identity with the transgene itself, recombination would result in gene replacement. In the
case of identity with border regions, recombination could result in the insertion of additional DNA
sequences in bacteria and thus confer the potential for new properties.
Soybean DAS-68416-4 contains genetic elements originating or derived from bacteria
(Section 3.1.1.1). These are: (1) a plant codon-optimised version of the aad-12 gene from the bacterium
D. acidovorans conferring tolerance to 2,4-D; (2) a plant codon-optimised version of the pat gene from
the bacterium S. viridochromogenes conferring tolerance to herbicides containing glufosinate-
ammonium; (3) two untranslated regions (UTR) comprising the transcriptional terminator and
polyadenylation site of ORF23 and ORF1 from plasmid pTi15955 (AtuORF23 and AtuORF1, respectively),
from A. tumefaciens; and (4) an intervening sequence from the Ti plasmid C58 of A. tumefaciens.
Bioinformatic analyses of the inserted DNA conﬁrmed that the plant codon-optimised bacterial
genes aad-12 and pat did not provide sufﬁcient sequence identity to facilitate homologous
recombination. However, sufﬁcient sequence identity with bacterial DNA was found for the AtuORF23
and AtuORF1 sequence, ﬂanking the pat gene. Double homologous recombination of transgenic plant
DNA with the plasmid of A. tumefaciens could result in an insertion of the pat gene onto a pTI15955
or highly similar plasmid.
A. tumefaciens occurs in soil, water and in the plant rhizosphere. It is therefore not expected to be
prevalent in the main receiving environments, i.e. the gastrointestinal tract of humans or animals.
However, occurrence of the recombinant genes outside of the immediate receiving environment
54 Dossier: Part I – Section D6.
Scientiﬁc opinion on GM soybean DAS-68416-4
www.efsa.europa.eu/efsajournal 22 EFSA Journal 2017;15(3):4719
(through faecal material) in soils cannot be ruled out, and is therefore also considered when assessing
the risks associated with a horizontal gene transfer.
The theoretically possible double homologous recombination between both sequences in soybean
DAS-68416-4 and pTi15955 in A. tumefaciens could result in the insertion of the plant-codon optimised
pat gene including its plant viral promoter. Such a recombination event, however, is expected to be
expressed at low levels by the plant viral promoter. Compared to the natural bacterial variants of the
pat gene, it is likely that the plant-optimised version results in a less functional enzyme in bacteria.
The insertion of the pat gene on the Ti plasmid would result in a dysfunctional plasmid due to the loss
of a large fragment between ORF23 and ORF1. Furthermore, the double homologous recombinant and
insertion of the pat gene would delete the bacterial potential for crown gall formation, due to the loss
of plasmid encoded genes between ORF23 and ORF1.
In addition to homology-based recombination processes, non-homologous (illegitimate)
recombination that does not require the presence of DNA similarity between the recombining DNA
molecules is theoretically possible. However, the transformation rates for illegitimate recombination
were considered to be 1010-fold lower than for homologous recombination (H€ulter and Wackernagel,
2008; EFSA, 2009) and have not never been detected for GM plants and bacteria, even in studies that
have directly exposed bacteria to high concentrations of GM plant DNA (EFSA, 2009).
In summary, the GMO Panel identiﬁed a potential for an increased likelihood for horizontal gene
transfer of a plant-optimised pat gene from soybean DAS-68416-4 to a plasmid of a soil bacterium by
double homologous recombination. This recombination would occur at the cost of inefﬁcient expression
of a plant-optimised protein and loss of the potential of the bacterial host for crown-gall formation.
Also, considering the natural abundance of pat as well as aad-12 genes in environmental bacteria, the
unlikely, but theoretically possible, transfer of the recombinant plant-codon optimised genes and
promoter sequences from soybean DAS-68416-4 to bacteria does not give rise to a safety concern.
2) Plant-to-plant gene transfer55
Considering the scope of the application EFSA-GMO-NL-2011-91 and the biology of soybean, the
potential of occasional feral GM soybean plants originating from seed import spills to transfer
recombinant DNA to sexually cross-compatible plants and the environmental consequences thereof
were considered.
The genus Glycine is divided into two distinct subgenera: Glycine and Soja. The subgenus Glycine
contains 16 perennial wild species, while the cultivated soybean, G. max, and its wild and semiwild
annual relatives, Glycine soja and Glycine gracilis, are classiﬁed in the subgenus Soja (OECD, 2000).
Owing to the low level of genomic similarity among species of the genus Glycine, G. max can cross
with only other members of the Glycine subgenus Soja under natural conditions (Singh et al., 1987;
Hymowitz et al., 1998; Lu, 2005). Hence, the three species of the subgenus Soja are capable of cross-
pollination and the hybrid seed that is produced can germinate normally and produce plants with
fertile pollen and seed (Abe et al., 1999; Nakayama and Yamaguchi, 2002). Since G. soja and
G. gracilis are indigenous to China, Taiwan, Korea, Japan, the far-east region of Russia, Australia, the
Philippines and the South Paciﬁc, and since they have not been reported in other parts of the world
where the cultivated soybean is grown (Dorokhov et al., 2004; Lu, 2005), the plant-to-plant gene
transfer from soybean is restricted to cultivated areas and occasional soybean plants resulting from
seed spillage in the EU.
Soybean is an annual, almost completely self-pollinating crop with a percentage of cross-pollination
usually below 1% (OECD, 2000; Ray et al., 2003; Lu, 2005; Yoshimura et al., 2006; Abud et al., 2007).
Soybean pollen dispersal is limited because the anthers mature in the bud and directly pollinate the
stigma of the same ﬂower (OECD, 2000).
However, cross-pollination rates as high as 6.3% have been reported for closely spaced plants (Ray
et al., 2003), suggesting the potential for some within-crop gene ﬂow in soybean. These results
indicate that natural cross-pollination rates can ﬂuctuate signiﬁcantly among different soybean varieties
under particular environmental conditions, such as favourable climate for pollination and an abundance
of pollinators (Caviness, 1966; Gumisiriza and Rubaihayo, 1978; Kikuchi et al., 1993; Ahrent and
Caviness, 1994; Ray et al., 2003; Lu, 2005).
For plant-to-plant gene transfer to occur, imported soybean DAS-68416-4 seeds need to be
processed outside the importing ports, transported into regions of soybean production in Europe,
spilled during transportation, germinate and develop into plants in the very close vicinity of soybean
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ﬁelds, and there needs to be an overlap of ﬂowering periods and environmental conditions favouring
cross-pollination. It must be noted that most soybean DAS-68416-4 seeds are processed in the
countries of production or in ports of importation. The overall likelihood of cross-pollination between
occasional feral GM soybean plants and cultivated soybean is therefore extremely low.
In conclusion, even if cross-pollination would occur, the GMO Panel is of the opinion that the
likelihood of environmental effects as a consequence of the spread of genes from occasional feral GM
soybean plants in Europe will not differ from that of conventional soybean varieties.
Interactions of the GM plant with target organisms56
Considering the scope of application EFSA-GMO-NL-2011-91, potential interactions of occasional
feral soybean DAS-68416-4 plants arising from seed import spills with target organisms are not
considered a relevant issue by the GMO Panel.
Interactions of the GM plant with non-target organisms57
Considering the scope of the application EFSA-GMO-NL-2011-91, and the low level of exposure to
the environment, potential interactions of spilled seeds or occasional feral soybean DAS-68416-4 plants
arising from seed import spills with non-target organisms are not considered a relevant issue by the
GMO Panel.
Interactions with the abiotic environment and biogeochemical cycles58
Considering the scope of the application EFSA-GMO-NL-2011-91, and the low level of exposure to
the environment, potential interactions with the abiotic environment and biogeochemical cycles are not
considered a relevant issue by the GMO Panel.
3.4.1.2. Post-market environmental monitoring59
The objectives of a PMEM plan according to Annex VII of Directive 2001/18/EC are to: (1) conﬁrm
that any assumption regarding the occurrence and impact of potential adverse effects of the GMO, or
its use, in the ERA are correct; and (2) identify the occurrence of adverse effects of the GMO, or its
use, on human health or the environment that were not anticipated in the environmental risk
assessment.
Monitoring is related to risk management, and thus a ﬁnal adoption of the PMEM plan falls outside
the mandate of EFSA. However, the GMO Panel gives its opinion on the scientiﬁc content of the PMEM
plan provided by the applicant (EFSA, 2006b; EFSA GMO Panel, 2011b).
The PMEM plan proposed by the applicant for soybean DAS-68416-4 includes: (1) the description of
an approach involving operators (federations involved in soybean import and processing), reporting to
the applicant, via a centralised system, any observed adverse effect(s) of GMOs on human health and
the environment; (2) a coordinating system newly established by EuropaBio for the collection of the
information recorded by the various operators; and (3) the use of networks of existing surveillance
systems (Lecoq et al., 2007; Windels et al., 2008). The applicant proposes to submit a PMEM report on
an annual basis, and a ﬁnal report at the end of the consent period.
The GMO Panel considers the scope of the PMEM plan provided by the applicant is consistent with
the scope of soybean DAS-68416-4. As the ERA does not cover cultivation and did not identify
potential adverse environmental effects from soybean DAS-68416-4, no case-speciﬁc monitoring is
necessary. The GMO Panel agrees with the reporting intervals proposed by the applicant in the PMEM
plan.
3.4.2. Conclusions on the environmental risk assessment and monitoring plan
In the case of accidental release into the environment of viable seeds of soybean DAS-68416-4,
there are no indications of an increased likelihood of establishment and spread of occasional feral
soybean DAS-68416-4 plants, unless these plants are exposed to the intended herbicides. The GMO
Panel is of the opinion that the latter will not result in different environmental impacts compared to
conventional soybean. Considering the scope of the application EFSA-GMO-NL-2011-91, interactions
with the biotic and abiotic environment are not considered to be relevant issues. The unlikely, but
56 Dossier: Part I – Sections D8 and D9.4.
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theoretically possible, transfer of the recombinant pat gene from soybean DAS-68416-4 to bacteria
does not give rise to a safety concern as these genes will not confer a selective advantage to bacteria.
Therefore, considering the introduced traits, the outcome of the comparative analysis, the routes of
exposure and the limited exposure levels, the GMO Panel concludes that soybean DAS-68416-4 would
not raise safety concerns in the event of accidental release of viable GM soybean seeds into the
environment.
The scope of the PMEM plan provided by the applicant and the reporting intervals are in line with
the intended uses of soybean DAS-68416-4 and the GMO Panel guidelines on the PMEM of GM plants.
In addition, the GMO Panel acknowledges the approach proposed by the applicant to put in place
appropriate management systems to restrict environmental exposure in cases of accidental release of
viable seeds of soybean DAS-68416-4.
4. Conclusions
The GMO Panel was asked to carry out a scientiﬁc assessment of soybean DAS-68416-4 for import,
processing and food and feed uses in accordance with Regulation (EC) No 1829/2003.
The molecular characterisation data and bioinformatics analyses did not identify issues requiring
further assessment for food/feed safety.
The agronomic and phenotypic characteristics of soybean DAS-68416-4 tested revealed no relevant
differences between soybean DAS-68416-4 and its conventional counterpart, except for ‘days to 50%
ﬂowering’ for the GM soybean not treated with the intended herbicides. The compositional analysis
identiﬁed no differences between soybean DAS-68416-4 and its conventional counterpart that required
further assessment for food/feed safety, except for a higher lectin activity (increased up to 36%) in
soybean DAS-68416-4. The increase in lectin activity is unlikely to raise additional concerns for food/
feed safety and nutrition for soybean DAS-68416-4 as compared to its conventional counterpart and
the non-GM commercial varieties. No concerns were identiﬁed regarding the potential toxicity or
allergenicity of the newly expressed AAD-12 and PAT proteins, and no evidence was found that the
genetic modiﬁcation might signiﬁcantly change the overall allergenicity of soybean DAS-68416-4. The
GMO Panel concludes that soybean DAS-68416-4, assessed in this application, is as safe and as
nutritious as its conventional counterpart and the non-GM soybean reference varieties tested. The
GMO Panel considers that post-market monitoring of food/feed derived from soybean DAS-68416-4 is
not necessary, given the absence of safety concerns identiﬁed.
The GMO Panel concludes that there is a very low likelihood of environmental effects resulting from
the accidental release of viable seeds from soybean DAS-68416-4 into the environment. Considering
the scope of the application with regard to food and feed uses, interactions with the biotic and abiotic
environment are not considered an issue. Risks associated with an unlikely, but theoretically possible,
horizontal gene transfer from soybean DAS-68416-4 to bacteria have not been identiﬁed. The scope of
the PMEM plan provided by the applicant is in line with the intended use of soybean DAS-68416-4.
In conclusion, the GMO Panel considers that the information available for soybean DAS-68416-4
addresses the scientiﬁc comments raised by the Member States and that soybean DAS-68416-4, as
described in this application, is as safe as its conventional counterpart and the tested non-GM soybean
reference varieties with respect to potential effects on human and animal health and the environment
in the context of the scope of this application.
Documentation provided to EFSA
1) Letter from the Competent Authority of the Netherlands received on 19 January 2011
concerning a request for placing on the market of genetically modiﬁed soybean DAS-68416-
4 submitted by Dow AgroSciences LLC in accordance with Regulation (EC) No 1829/2003
(application reference EFSA-GMO-NL-2011-91).
2) Acknowledgement letter dated 7 February 2011 from EFSA to the Competent Authority of
the Netherlands.
3) Letter from EURL-JRC dated 15 February 2011 requesting additional information under
completeness check.
4) Letter from EFSA to applicant dated 4 March 2011 requesting additional information under
completeness check.
5) Letter from applicant to EFSA received on 23 March 2011 providing additional information
under completeness check.
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6) Letter from EFSA to applicant dated 12 April 2011 requesting additional information under
completeness check.
7) Letter from EURL-JRC dated 18 April 2011 requesting additional information under
completeness check.
8) Letter from applicant to EFSA received on 5 May 2011 providing additional information
under completeness check.
9) Letter from EFSA to applicant dated 24 May 2011 requesting additional information under
completeness check.
10) Letter from applicant to EFSA received on 27 June 2011 providing additional information
under completeness check.
11) Letter from EFSA to applicant dated 20 July 2011 requesting additional information under
completeness check.
12) Letter from applicant to EFSA received on 19 August 2011 providing additional information
under completeness check.
13) Letter from EFSA to applicant dated 8 September 2011 delivering the ‘Statement of
Validity’ of application EFSA-GMO-NL-2010-91 for placing on the market of genetically
modiﬁed soybean DAS-68416-4 submitted by Dow AgroSciences LLC in accordance with
Regulation (EC) No 1829/2003.
14) Letter from EFSA to applicant dated 5 December 2011 requesting additional information
and stopping the clock.
15) Letter from EFSA to applicant dated 30 January 2012 requesting additional information and
maintaining the clock stopped.
16) Letter from EFSA to applicant dated 6 March 2012 asking for timeline for submission of
responses.
17) Letter from applicant to EFSA received on 16 March 2012 extending the timeline for
submission of responses.
18) Letter from applicant to EFSA received on 13 April 2012 providing additional information.
19) Letter from applicant to EFSA received on 13 April 2012 providing additional information.
20) Letter from EURL-JRC to EFSA dated 16 April 2012 requesting EFSA to stop the clock.
21) Letter from EFSA to applicant dated 20 April 2012 requesting additional information (EURL-
JRC) and maintaining the clock stopped.
22) Email from Applicant to EURL-JRC dated 17 April 2012 providing additional information
requested under completeness check on 18 April 2011 and under risk assessment on 20 April
2012.
23) Email from EURL-JRC to EFSA dated 15 May 2012 requesting EFSA to re-start the clock.
24) Letter from EFSA to applicant, dated 9 July 2012, re-starting the clock on behalf of EURL-JRC.
25) Letter from applicant to EFSA, received on 7 August 2012, providing additional information
spontaneously.
26) Letter from applicant to EFSA, received on 27 August 2012, providing additional
information spontaneously.
27) Letter from EFSA to applicant dated 7 September 2012 requesting additional information
and stopping the clock.
28) Letter from applicant to EFSA received on 19 November 2012 providing a timeline for
submission of responses.
29) Letter from applicant to EFSA received on 19 April 2013 extending (1) the timeline for
submission of responses.
30) Letter from applicant to EFSA received on 25 July 2013 extending (2) the timeline for
submission of responses.
31) Letter from applicant to EFSA received on 18 October 2013 providing additional information
32) Letter from EFSA to applicant dated 1 July 2014 requesting additional information and
maintaining the clock stopped.
33) Letter from applicant to EFSA received on 2 September 2014 providing additional information.
34) Letter from applicant to EFSA, received on 4 November 2014, providing additional information
spontaneously.
35) Letter from EFSA to applicant dated 28 November 2014 requesting additional information
and maintaining the clock stopped.
36) Letter from applicant to EFSA received on 16 December 2014 providing additional information.
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37) Letter from EFSA to applicant dated 16 February 2015 requesting additional information
and maintaining the clock stopped.
38) Letter from EFSA to applicant dated 19 February 2015 requesting additional information
and maintaining the clock stopped.
39) Letter from applicant to EFSA received on 19 February 2015 providing additional information
40) Letter from EFSA to applicant dated 6 March 2015 requesting additional information and
maintaining the clock stopped.
41) Letter from applicant to EFSA received on 12 March 2015 providing additional information.
42) Letter from applicant to EFSA received on 16 March 2015 providing additional information.
43) Letter from EFSA to applicant dated 1 April 2015 requesting additional information and
maintaining the clock stopped.
44) Letter from applicant to EFSA received on 11 June 2015 providing additional information.
45) Letter from EFSA to applicant dated 24 June 2015 requesting additional information and
maintaining the clock stopped.
46) Letter from applicant to EFSA received on 22 July 2015 providing additional information.
47) Letter from EFSA to applicant dated 15 September 2015 requesting additional information
and maintaining the clock stopped.
48) Letter from applicant to EFSA received on 25 September 2015 providing additional
information.
49) Letter from EFSA to applicant dated 2 October 2015 requesting additional information and
maintaining the clock stopped.
50) Letter from applicant to EFSA received on 23 November 2015 providing additional information.
51) Letter from applicant to EFSA, received on 7 December 2015, providing clariﬁcations
related to information received on 23 November 2015.
52) Letter from applicant to EFSA received on 22 December 2015 providing additional
information spontaneously.
53) Letter from applicant to EFSA received on 4 March 2016, requesting EFSA to disregard the
information regarding EFSA’s request of 2 October 2015 (received on 23 November 2015).
54) Letter from EFSA to applicant dated 23 March 2016 requesting additional information and
maintaining the clock stopped.
55) Email from applicant to EFSA received on 31 March 2016 providing sequencing information.
56) Letter from EURL-JRC to EFSA dated 22 April 2016 requesting EFSA to stop the clock.
57) Email from EFSA to applicant dated 26 April 2016 requesting additional information (EURL-
JRC) and maintaining the clock stopped.
58) Letter from applicant to EFSA received on 29 April 2016 providing additional information.
59) Letter from applicant to EFSA received on 13 May 2016 providing additional information;
this letter contains information submitted spontaneously.
60) Letter from EFSA to applicant dated 26 May 2016 requesting additional information and
maintaining the clock stopped.
61) Letter from applicant to EFSA received on 13 June 2016 providing additional information.
62) Email from EURL-JRC to EFSA dated 7 September 2016 requesting EFSA to re-start the
clock.
63) Letter from EFSA to applicant, dated 28 September 2016, re-starting the clock.
64) Letter from EFSA to applicant dated 29 September 2016 requesting additional information
and stopping the clock.
65) Letter from applicant to EFSA received on 26 October 2016 providing additional information.
66) Email from EFSA to applicant, dated 3 November 2016, re-starting the clock.
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Abbreviations
2,4-D 2,4-dichlorophenoxyacetic acid
AA amino acid
AAD-12 aryloxyalkanoate dioxygenase-12
ADF acid detergent ﬁbre
ANOVA analysis of variance
AtuORF Agrobacterium tumefaciens open reading frame
bp base pair
BSA bovine serum albumin
bw body weight
CsVMV Cassava vein mosaic virus
DM dry matter
ELISA enzyme-linked immunosorbent assay
ERA environmental risk assessment
EURL-JRC European Union Reference Laboratories-Joint Research Centre
FA fatty acid
FAO Food and Agricultural Organisation of the United Nations
FW fresh weight
GLP Good Laboratory Practice
GM genetically modiﬁed
GMO genetically modiﬁed organism
GMO Panel EFSA Panel on Genetically Modiﬁed Organisms
HGT horizontal gene transfer
HU haemagglutination unit
IgE immunoglobulin E
NDF neutral detergent ﬁbre
OECD Organisation for Economic Co-operation and Development
ORF open reading frame
PAT phosphinothricin acetyltransferase
PCR polymerase chain reaction
PLT platelets
PMEM post-market environmental monitoring
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RET reticulocyte
RBC red blood cells
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis
T-DNA transfer-deoxyribonucleic acid
UTR untranslated region
WBC white blood cells
WSR Wilcoxon Signed Rank
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